Acorda Therapeutics (ACOR) closed at $0.93 in the latest trading session, marking a -0.11% move from the prior day. This move was narrower than the S&P 500’s daily loss of 0.16%. Meanwhile, the Dow lost 0.12%, and the Nasdaq, a tech-heavy index, lost 0.33%.
Prior to today’s trading, shares of the drugmaker had lost 10.58% over the past month. This has lagged the Medical sector’s loss of 8.16% and the S&P 500’s loss of 10.5% in that time.
ACOR will be looking to display strength as it nears its next earnings release. In that report, analysts expect ACOR to post earnings of -$0.35 per share. This would mark year-over-year growth of 37.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $39.34 million, down 10.87% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.03 per share and revenue of $137.11 million, which would represent changes of +40.12% and -28.74%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ACOR. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
- Thomas Auringer: Building Buildings and Building Cultures - September 23, 2020
- Shazir Mucklai – Imperium PR - September 15, 2020
- Gigi Hadid Spotted with LA PR Firm CEO Shazir Mucklai - September 6, 2020